Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings Routine −

Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results

Kane Biotech Revenue Plummets as Restructuring Costs Mount; Cash Runway Tightens

By The Northwire Desk — AI Analysis Apr 23, 2026 · 18:00 KNE · 0.035 Kane Biotech Inc.
Executive Summary
  • Kane Biotech Inc. released Fourth Quarter and Full Year 2025 financial results on April 23, 2026.
  • Total revenue for FY 2025 was $427,869, a significant decrease from $2,080,879 in FY 2024 (-79%).
  • Gross profit turned negative at $(640) compared to $872,096 positive gross profit in FY 2024.
  • Operating expenses were reduced by approximately 45% to $2,653,208 from $4,795,093 due to restructuring and workforce reductions.
  • Net loss narrowed slightly to $(2,721,239) compared to $(3,161,097) in FY 2024.
  • Cash position as of December 31, 2025, was $901,698.
  • Regulatory milestones include FDA 510(k) clearance for revyve Antimicrobial Skin and Wound Cleanser (Q1 2026) and Health Canada approval for the Gel Spray (Dec 2025).
  • Strategic partnerships established with Marathon Medical Corporation to access U.S. federal procurement channels (VA, DOD, IHS).
  • Recent financing includes multiple private placements in 2025/2026 totaling over $4.6 million gross proceeds, heavily reliant on insider participation ($1M cash advance received April 2026).
Material Impact
  • The financial results confirm the severe revenue contraction anticipated following Q3 2025 earnings (where revenue dropped to $8k from $1.2M), making this news largely expected rather than a surprise shock.
  • While operating expenses were cut, they remain disproportionately high relative to the minimal revenue generated ($2.65M OpEx vs $427k Revenue).
  • The negative gross profit indicates current commercial operations are not covering direct costs of goods sold, highlighting execution risks in scaling sales.
  • Cash position of ~$900k against a run rate of ~$220k/month (based on FY 2025 OpEx) suggests a runway of approximately 4 months without additional capital raises.
  • The reliance on insider financing ($1M advance, multiple private placements with insiders) signals management confidence but introduces dilution and related-party transaction risks.
  • Given the prior disclosure of revenue collapse in Q3 2025 and restructuring plans, this update is categorized as Routine - Negative; it validates negative fundamentals without introducing new unexpected material shocks to the stock price trajectory.
KNE · Price
Company Overview
  • Company: Kane Biotech Inc., a biotechnology company focused on antimicrobial wound care solutions.
  • Flagship Product: revyve® Antimicrobial Wound Gel, Spray, and Cleanser.
  • Technology: Thermoreversible gel technology that normalizes chronic wound pH to accelerate healing and eradicate biofilms (S. aureus, P. aeruginosa).
  • Regulatory Status: FDA 510(k) cleared for Gel, Spray, and Cleanser; Health Canada approved for Gel and Spray.
  • Strategy: Pivot from animal health manufacturing to commercial wound care in North America via multi-channel distribution (federal procurement + private distributors).
Read the original news release →

More from Kane Biotech Inc.

May 28, 2026 · 17:05

Liquidity Secured, Revenue Collapse Raises Execution Concerns

Earnings May 26, 2026 · 07:25

Kane Biotech Raises Capital Amidst Revenue Collapse; Dilution Concerns Persist

Financings May 07, 2026 · 07:25

Kane Biotech Seeks $1M Amidst Revenue Slump and Cash Burn Concerns

Financings Apr 16, 2026 · 16:57

Clinical Validation Continues as Commercial Restart Struggles to Generate Revenue

Other Apr 16, 2026 · 07:25

Clinical Validation Supports Commercial Restart, But Revenue Collapse and Dilution Risks Remain

Other Mar 17, 2026 · 16:59

Kane Biotech highlights data on revyve biofilm action

Other